Last week, WHO granted authorisation for the vaccine, produced by EuBiologics, the same manufacturer responsible for the current formulation. This new iteration, dubbed Euvichol-S, boasts a streamlined composition requiring fewer ingredients, rendering it more cost-effective and expeditiously manufacturable compared to its predecessor.
Late-stage research conducted in Nepal demonstrated the vaccine’s efficacy in preventing the diarrheal disease, prompting WHO’s approval. This decision enables donor agencies like the Vaccine Alliance (Gavi) and UNICEF to procure the vaccine for distribution in impoverished nations. Leila Pakkala, Director of UNICEF’s Supply Division, hailed the approval, anticipating a substantial increase in vaccine supplies by over 25%.
